Skip to content

Gross Profit at other companies

Eli Lilly logo
Eli LillyLLY
$16.22B+54.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$54.21M+10.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$34.32M+80.1%
LQD
Liquidia CorporationLQDA
$1.6M+6.5%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s gross profit?
Gyre Therapeutics, Inc. (GYRE) reported gross profit of $21.29M in Q1 2026.
How has Gyre Therapeutics, Inc.'s gross profit changed year-over-year?
Gyre Therapeutics, Inc.'s gross profit increased by 0.6% year-over-year, from $21.16M to $21.29M.
What is the long-term trend for Gyre Therapeutics, Inc.'s gross profit?
Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s gross profit has grown at a 4.5% compound annual growth rate (CAGR), from $97.5M to $111.17M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.